‘300억 목표’ 시지바이오, 中 의료미용 기업과 필러 시장 정조준

CGBio's launch of Eloyan through a strategic partnership with local distributor UPS BIO highlights the critical role of regional adaptation and localized distribution networks in China's medical aesthetics market. By combining global product quality with local market knowledge and KOL marketing capabilities, the company is targeting 300 billion won in revenue, reflecting the significant growth opportunity in Asia's largest aesthetic market. This multi-brand approach demonstrates how foreign companies must balance global standards with localized strategies to compete effectively in China's highly fragmented medical beauty sector.